Powell, M. A., Zub, O., Raashouu-Jensen, N., Gilbert, L., Beijers, A. J., Willmott, L., Gropp-Meier, M., Ring, K., Nilsen, E. B., Armstrong, A. J., Nevadunsky, N. S., Gill, S., Holloway, R. W., Miller, E., Diaz, J. P., Teneriello, M., Mays, K., Austin, L. K., McCourt, C. K., Noettrup, T. J. (2026). Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5501